PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ -- ASMS 2021 – Biopharmaceutical laboratories can now benefit from high-quality mass information delivered by Orbitrap technology for molecule attribute monitoring in development and quality control (QC). This offering is a part of a multi-attribute method (MAM) workflow that offers reduced downtime and maintenance and provides seamless method transfers from development to QC.

The Thermo Scientific Orbitrap Exploris MX mass detector offers high resolution accurate mass (HRAM) data for intact analysis of monoclonal antibodies (mAbs), oligonucleotide mass determination and peptide mapping, making it ideal for biopharma process confirmation. The offering enables accelerated drug characterization processes in QC and productivity improvements by fully integrating the Orbitrap Exploris MX into the MAM 2.0 workflow, thereby replacing multiple assays into one information rich mass spectrometric assay. Furthermore, the hardware and software transition from using the Thermo Scientific Orbitrap Exploris 240 mass spectrometer in development stage to using the Orbitrap Exploris MX mass detector in QC stage is made seamless by the compliance-ready Thermo Scientific Chromeleon chromatography data system (CDS) software.

Thermo Fisher Scientific is showcasing its new offering during the 69^th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held October 31-November 4, in the Pennsylvania Convention Center, Philadelphia, Pennsylvania.

"The Orbitrap Exploris MX mass detector is integrated with our MAM 2.0 offering to help streamline workflows, provide our customers with confidence in their results, and simplify workflow operation," said Iain Mylchreest, vice president, research and development, analytical instruments, Thermo Fisher Scientific. "We strive to exceed our customers' needs by providing built-for-purpose, user-friendly solutions that deliver high-quality and reliable data."

Sara Carillo, biopharmaceutical application development team leader at National Institute for Bioprocessing Research and Training (NIBRT), Ireland, said, "The new Thermo Scientific Orbitrap Exploris MX has everything you need for biopharmaceuticals characterization, including robustness, flexibility and accuracy. It is the ideal foundation for one's MAM journey."

Other advantages of the Orbitrap Exploris MX include:

• Easy adoption for contract research, development and manufacturing organizations enabled by rapid calibration procedures, built-in methods, and reliable performance
• Orbitrap technology which provides market-leading resolution, mass accuracy and sensitivity.
• Simplified implementation of MAM into QC

For more information on the Thermo Scientific Orbitrap Exploris MX mass detector, please visit www.thermofisher.com/OrbitrapExplorisMX, or join us at ASMS 2021 from October 31-November 4, 2021.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Media Contact Information:

Laura Bright
Thermo Fisher Scientific
+1 562-335-8318 
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

SOURCE Thermo Fisher Scientific